12:00 AM
 | 
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Denosumab: Additional Phase III data

Additional data from a double-blind, head-to-head, international Phase III trial in 1,901 patients with advanced prostate cancer showed that the median time to first on-study SRE, the primary endpoint, was 20.7 months for denosumab vs. 17.1 months for Zometa (p=0.0002 for non-inferiority and p=0.008 for superiority). Patients received 120 mg subcutaneous denosumab or 4 mg Zometa as a 15-minute infusion every 4 weeks. Data were published in The Lancet....

Read the full 331 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >